In this article, we will discuss: 11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate. Numerous quickly expanding businesses are arising in the genomics industry as a result of technological advancements that significantly reduce the cost, accuracy, and time required to map a human being’s entire genome. Investors in innovation, like Cathie Wood of Ark Investment Management, believe that these developments are bringing about a “Genomic Revolution.”
The 32nd Plant and Animal Genomics Conference, held in San Diego from January 10-15, 2025, brought attention to how quickly agricultural genomics technology is developing. One noteworthy finding was the dramatic drop in sequencing costs. What took the original Human Genome Project 13 years and $3 billion can now be performed for less than $200 in a matter of days, with new platforms promising $100 per human genome.
These developments are opening up practical research and development in a variety of crops, such as pomegranates and wheat, with a spotlight on yield improvement and climate adaptation. Breeding cycles are being accelerated, especially for perennial crops, by methods like transgenics, genome editing, and marker-assisted breeding. The global effect is nonetheless constrained by regulatory complexity, particularly by uneven policies between regions such as the EU.
With that said, here are the 11 Best Genomics Stocks to Buy According to Hedge Funds.
A laboratory technician using high tech equipment to sequence cancer genomics.
Methodology:
For this article, we sifted through Genomics online rankings to form an initial list of the 20 Best Genomics Stocks. From the resultant dataset, we chose 11 stocks with the highest number of hedge fund investors, using Insider Monkey’s database of 1000 hedge funds in Q1 2025 to gauge hedge fund sentiment for stocks. We have used the stock’s revenue growth year-over-year as a tie-breaker in case two or more stocks have the same number of hedge funds invested.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
11. Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Number of Hedge Fund Holders: 29
Intellia Therapeutics, Inc. (NASDAQ:NTLA) presented encouraging three-year follow-up data from their Phase 1 trial of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE) at the EAACI Congress 2025.
All 10 patients were free of attacks and treatment for a median of 23 months after receiving a single dose of lonvo-z, which led to a 98% mean reduction in monthly HAE attacks. Positive safety results were maintained across all treatment dosages. The current Phase 3 HAELO trial has a majority of U.S. enrollment and has completed screening ahead of schedule. Intellia Therapeutics, Inc. (NASDAQ:NTLA) plans to launch in 2027 after submitting a BLA in 2026.
Lonvo-z (NTLA-2002) is an experimental in vivo CRISPR-based gene editing therapy that targets the KLKB1 gene to prevent HAE attacks. The FDA has designated it as an Orphan Drug and RMAT, while the EMA has designated it as PRIME, among other regulatory classifications.
Administered intravenously at doses ranging from 25 to 75 mg, the therapy demonstrated dose-dependent kallikrein protein decrease and long-term efficacy, with no major treatment-related side effects recorded. Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the Best Genomics Stocks.
10. Twist Bioscience Corporation (NASDAQ:TWST)
Number of Hedge Fund Holders: 30
Revenue growth (YoY): 27.69%
Twist Bioscience Corporation (NASDAQ:TWST) and Element Biosciences have expanded their relationship to produce end-to-end Next Generation Sequencing (NGS) solutions.
Twist Bioscience Corporation (NASDAQ:TWST)’s library prep and target enrichment workflows are now integrated with Element’s AVITI™ devices and Trinity™ flowcells. Twist will be the only supplier of the new Trinity kits for the AVITI platform as a result of the deal. Both businesses will collaborate on commercial efforts to increase customer access to high-performance NGS technologies.
The expanded relationship builds on past success, including Twist Bioscience Corporation (NASDAQ:TWST)’s Trinity solution for one-hour quick hybridization. The partnership will improve workflows for agbio, genomics, and clinical research by streamlining hybrid capture both off and on sequencers, according to Twist CEO Emily Leproust.
Element Biosciences CEO Molly He highlighted that the combination of Twist Bioscience Corporation (NASDAQ:TWST)’s prep capabilities and Trinity’s focused sequencing is essential to advancing science. The partnership will provide researchers with platform flexibility, uniformity, and quality by extending NGS capabilities beyond exome sequencing. It is ranked tenth on our list of the Best Genomics Stocks.
9. Verve Therapeutics, Inc. (NASDAQ:VERV)
Number of Hedge Fund Holders: 30
Revenue growth (YoY): 174.98%
Eli Lilly and Company will buy Verve Therapeutics, Inc. (NASDAQ:VERV) for up to $1.3 billion.
Depending on future milestones, Lilly will pay $10.50 per share in cash, or roughly $1.0 billion, plus a contingent value right of up to $3.00 per share. The purchase is anticipated to be completed in Q3 2025 and represents a 113% premium over Verve Therapeutics, Inc. (NASDAQ:VERV)’s 30-day average share price as of June 16, 2025.
Single-dose gene-editing therapies for atherosclerotic cardiovascular disease are being developed by Verve Therapeutics, Inc. (NASDAQ:VERV), including their flagship program VERVE-102, which targets PCSK9. The medication, which is currently in Phase 1b and has been granted FDA Fast Track designation, has the potential to transform care for patients suffering from heterozygous familial hypercholesterolemia and early coronary artery disease.
According to Lilly, Verve Therapeutics, Inc. (NASDAQ:VERV)’s platform strengthens its cardiometabolic pipeline. Sekar Kathiresan, CEO of Verve, stressed the company’s goal of moving from chronic to one-time care. Insiders of the firm who own 17.8% of the company have decided to tender. It is one of the Best Genomics Stocks.
8. 10x Genomics, Inc. (NASDAQ:TXG)
Number of Hedge Fund Holders: 35
Revenue growth (YoY): -1.28%
10x Genomics, Inc. (NASDAQ:TXG) has announced a global settlement agreement with Bruker Corporation, which resolves all outstanding patent litigation between the two firms.
As per the agreement, from Q3 2025 to Q2 2026, Bruker will pay 10x Genomics, Inc. (NASDAQ:TXG) $68 million in equal quarterly installments. Furthermore, Bruker will pay continuous royalties on sales of spatial biology products for the duration of the licensed patents. Global patent cross-licenses and the termination of all legal actions in the United States, Germany, and the European Unified Patent Court are part of the settlement.
10x Genomics, Inc. (NASDAQ:TXG), a leader in single-cell and spatial biology, pointed out the need for intellectual property protection to promote scientific innovation. CEO Serge Saxonov regarded the outcome as a validation of the company’s vision and dedication to innovation.
Eric Whitaker, Chief Legal Officer, noted the robustness of the firm’s IP portfolio and its fundamental function in spatial biology. The settlement makes it possible to keep funding upcoming innovations. It is among the Best Genomics Stocks.
7. uniQure N.V. (NASDAQ:QURE)
Number of Hedge Fund Holders: 35
Revenue growth (YoY): 71.17%
Lake Street Capital reiterated its Buy rating and $30 price target for ClearPoint following uniQure N.V. (NASDAQ:QURE) regulatory update on AMT-130, an experimental gene therapy for Huntington’s disease.
uniQure N.V. (NASDAQ:QURE) declared that it has partnered with the FDA to seek an expedited approval process for AMT-130. If the trials go well and the FDA approves it, Lake Street sees AMT-130 as maybe ClearPoint’s first “meaningful partner asset.”
ClearPoint provides disposables valued at almost $20,000 for each AMT-130 infusion, suggesting a significant financial benefit associated with the therapy’s effectiveness. The FDA’s support might result in the approval by the end of 2026, which would have a big effect on ClearPoint’s financial standing and confirm its strategic focus on image-guided neurosurgery and gene therapy delivery.
According to Lake Street, this regulatory milestone increases clarity on ClearPoint’s contribution to the advancement of clinical-stage gene treatments and provides further assurance regarding the clearance timeline for AMT-130.
6. Exact Sciences Corporation (NASDAQ:EXAS)
Number of Hedge Fund Holders: 41
Exact Sciences Corporation (NASDAQ:EXAS) has released fresh data from the Beta-CORRECT study that validates the clinical efficacy of its tumor-informed Oncodetect™ test for recurrence monitoring in stage II-IV colorectal cancer.
The findings, presented at ASCO 2025, revealed that patients with ctDNA-positive results after therapy and during surveillance had a 24- and 37-fold greater risk of recurrence, respectively. The business also disclosed plans to introduce a next-generation test in 2026 that will use Broad Institute’s MAESTRO technology, which can track up to 5,000 patient-specific variations and identify ctDNA levels below 1 part per million.
Oncodetect, which was created for molecular residual disease identification, has improved prognosis prediction over standard-of-care approaches in stage III colorectal cancer, as proven by both Alpha- and Beta-CORRECT trials.
The revised version uses whole-genome sequencing that is solely licensed from the Broad Institute to improve sensitivity and scalability. This is Exact Sciences Corporation (NASDAQ:EXAS)’s largest MRD clinical research to date, with over 400 patients enrolled, and it reflects the company’s ambition to enhance precision oncology through advances based on ctDNA. It is ranked sixth on our list of the Best Genomics Stocks.
5. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Number of Hedge Fund Holders: 43
The initial participant in the pivotal Phase 3 REVEAL trial, which is assessing ION582 for Angelman syndrome, a severe neurodevelopmental disease, has been dosed by Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).
The randomized, placebo-controlled research will include approximately 200 people with UBE3A gene deletions or mutations. The main goal of the 52-week trial will be expressive communication, and quarterly 40 mg or 80 mg dosages of ION582 will be evaluated. The trial intends to finish enrollment in 2026 and is based on positive Phase 1/2 HALOS results.’
ION582 is an antisense RNA treatment that inhibits UBE3A-ATS to promote UBE3A protein. The FDA has designated it as a Rare Pediatric Disease, Fast Track, and Orphan Drug. Globally, 1 in 21,000 individuals suffer from Angelman syndrome, which results in severe physical and cognitive impairments.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), which developed SPINRAZA and QALSODY, is expanding its neurology portfolio, with eight wholly owned treatments in development for rare and common disorders, including Alzheimer’s and Parkinson’s disease. It is among the Best Genomics Stocks.
4. Biogen Inc. (NASDAQ:BIIB)
Number of Hedge Fund Holders: 52
Biogen Inc. (NASDAQ:BIIB) has begun dosing in the global Phase 3 BRAVE trial to test omaveloxolone (SKYCLARYS®) in children aged 2 to 16 with Friedreich ataxia (FA), a rare neurological illness.
About 255 participants will be included in the randomized, double-blind experiment, which will have a 52-week treatment duration and an open-label extension. SKYCLARYS is now the only approved therapy for FA in people aged 16 and up, and it is available in more than 40 countries. The BRAVE research seeks to address a large unmet need in pediatric FA.
FA is a crippling neuromuscular disease that is inherited and usually first manifests in childhood. Patients typically lose their ability to move within 10 to 20 years following the onset of symptoms, and the average age of death is 37. SKYCLARYS has shown effectiveness in adults and was designated as an Orphan Drug, Fast Track, and Rare Pediatric Disease.
The primary endpoint of the BRAVE research is the Upright Stability Score, which is part of the modified FA rating scale and is used to assess progression in children. Global enrollment is still ongoing.
3. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Number of Hedge Fund Holders: 59
Gena Wang of Barclays kept BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) at a Buy rating with a price target of $86.00 in a report published on June 10.
According to BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s most recent earnings report, the firm made $745.15 million in revenue and $185.69 million in net profit for the quarter that ended on March 31. The company’s sales were $648.83 million, and its net profit was $88.66 million last year.
It is challenging to avoid past comparisons with Genzyme (bought by Sanofi) as BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) builds a portfolio of genetic-disease therapies. Despite having several authorized treatments, the firm spent years in the red due to commercialization and R&D costs, but analysts are optimistic about the long-term, profitable potential of its present portfolio. It is in a strong position because of its extensive internal pipeline and capacity to add expansion through strategic acquisitions.
2. Illumina, Inc. (NASDAQ:ILMN)
Number of Hedge Fund Holders: 60
Kyle Mikson, an analyst at Canaccord Genuity, increased his price objective for Illumina, Inc. (NASDAQ:ILMN) shares from $87 to $99 on June 11 while keeping his rating at Hold.
The announcement comes after Illumina, Inc. (NASDAQ:ILMN) CEO Jacob Thaysen stated in a podcast that when pricing pressures lessen, revenue improvements may be driven by robust volume growth from clinical customers. Thaysen stated that its long-term development plan is still in place, provided that the NovaSeq X sequencing system is adopted more widely. Canaccord is still on the sidelines even if there are indications that its performance will improve in the medium term.
The recent performance of Illumina, Inc. (NASDAQ:ILMN), a significant participant in sequencing and genomics technology, has been hampered by pricing challenges. CEO Jacob Thaysen highlighted the need for clinical volume increase in promoting both future revenue growth and recovery.
The implementation of the NovaSeq X platform will be essential to carrying out Illumina, Inc. (NASDAQ:ILMN)’s expansion goal. Canaccord’s raised target reflects cautious optimism about improving execution while remaining neutral overall. It is one of the Best Genomics Stocks.
1. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Number of Hedge Fund Holders: 66
UBS has maintained its Neutral rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and reduced its price objective from $633 to $560 on June 5, noting mixed corporate updates and recent pipeline advancements.
The Phase 2 COURAGE study interim readout, the Phase 3 AERIFY-1/2 trials results for itepekimab in COPD, the $256 million acquisition of 23andMe, and a license agreement with Hansoh for the ex-China rights to a Phase 3 GLP-1/GIP receptor agonist are among the noteworthy developments. UBS identifies Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s Eylea franchise’s ongoing weakening as a major short-term concern.
Recent strategic actions by Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), including licensing agreements and acquisitions, demonstrate that the company is expanding beyond its traditional ophthalmology portfolio. However, due to the difficulties the Eylea franchise is facing, market sentiment remains wary.
Although pipeline updates, such as the data from the COPD trial and the metabolic asset partnership with Hansoh, have long-term potential, UBS believes that these benefits are outweighed by the pressure from existing franchises, which supports the updated price target and Neutral position.
While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stock To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. 11 Best Genomics Stocks to Buy According to Hedge Funds is originally published on Insider Monkey. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
